OGNRegulatory•businesswire•
US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
Sentiment:Neutral (45)
Summary
(NYSE:OGN) SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--FDA Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp)
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 2, 2025 by businesswire